What’s new

• Q4 consolidated revenue rose 5.7% YoY to ₹40,973 million.
• Q4 EBITDA jumped 31.8% to ₹6,265 million, with margin hitting 15.3%.
• Full-year revenue grew 2.1% to ₹155,130 million.

Why it matters

The 31.8% EBITDA jump on modest 5.7% revenue growth signals a meaningful shift in product mix or cost structure. Hitting a 14-quarter margin high is a real operational improvement. The Egypt and Mexico projects must now build on that efficiency without diluting it.

What we’re watching

• Whether the 15.3% margin holds as new Egypt and Mexico capacity ramps in FY27.
• How West Asia conflict disruptions affect the timeline and cost of new international projects.
• If the Q4 strength was a one-off recovery or the start of a sustained profitability trend.

The full read

Uflex finished FY26 with its strongest quarter in over three years. Q4 EBITDA jumped 31.8% to ₹6,265 million on a 5.7% revenue rise to ₹40,973 million. The margin of 15.3% is the highest in 14 quarters. Full-year revenue growth of just 2.1% to ₹155,130 million was modest, making the Q4 surge look like a sharp recovery rather than a steady climb. Management pointed to better product mix and higher capacity utilization. The next phase is execution: a 12-billion unit aseptic plant in Egypt and a WPP bag facility in Mexico are both slated for H1 FY27 commissioning. The challenge is holding the new margin discipline while integrating international capacity against a backdrop of conflict and tariff noise. The 14-quarter high is a good starting point, but the annual numbers show how far the company has to go to make it stick.

Primary source: BSE · NSE